BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38471713)

  • 1. rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors.
    Lee M; Im SK; Baek S; Ji M; Kim M; Lee EJ; Ji ST; Ferrando-Martinez S; Wolfarth A; Lee JY; Kim D; Choi D
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy.
    Kim JH; Kim YM; Choi D; Jo SB; Park HW; Hong SW; Park S; Kim S; Moon S; You G; Kang YW; Park Y; Lee BH; Lee SW
    Clin Transl Immunology; 2020; 9(9):e1168. PubMed ID: 32994996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions.
    Kim S; Lee SW; Koh JY; Choi D; Heo M; Chung JY; Lee BH; Yang SH; Sung YC; Lee H; Shin EC; Park SH
    Blood Adv; 2022 Dec; 6(23):6093-6107. PubMed ID: 36206199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity.
    Lee JY; Lee E; Hong SW; Kim D; Eunju O; Sprent J; Im SH; Lee YJ; Surh CD
    Oncoimmunology; 2020; 9(1):1681869. PubMed ID: 32002288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy.
    Lee KJ; Choi D; Tae N; Song HW; Kang YW; Lee M; Moon D; Oh Y; Park S; Kim JH; Jeong S; Yang J; Park U; Hong DH; Byun MS; Park SH; Sohn J; Park Y; Im SK; Choi SS; Kim DH; Lee SW
    Cell Rep Med; 2024 May; 5(5):101567. PubMed ID: 38744277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8
    LaPorte KM; Hernandez R; Santos Savio A; Malek TR
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37270181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hIL-7-hyFc, A Long-Acting IL-7, Increased Absolute Lymphocyte Count in Healthy Subjects.
    Lee SW; Choi D; Heo M; Shin EC; Park SH; Kim SJ; Oh YK; Lee BH; Yang SH; Sung YC; Lee H
    Clin Transl Sci; 2020 Nov; 13(6):1161-1169. PubMed ID: 32339447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation.
    Lee J; Lee K; Bae H; Lee K; Lee S; Ma J; Jo K; Kim I; Jee B; Kang M; Im SJ
    Front Immunol; 2023; 14():1117092. PubMed ID: 37409128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors.
    Khan SM; Desai R; Coxon A; Livingstone A; Dunn GP; Petti A; Johanns TM
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.
    Campian JL; Ghosh S; Kapoor V; Yan R; Thotala S; Jash A; Hu T; Mahadevan A; Rifai K; Page L; Lee BH; Ferrando-Martinez S; Wolfarth AA; Yang SH; Hallahan D; Chheda MG; Thotala D
    Clin Cancer Res; 2022 Mar; 28(6):1229-1239. PubMed ID: 35031547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The primordial differentiation of tumor-specific memory CD8
    Huang Q; Wu X; Wang Z; Chen X; Wang L; Lu Y; Xiong D; Liu Q; Tian Y; Lin H; Guo J; Wen S; Dong W; Yang X; Yuan Y; Yue Z; Lei S; Wu Q; Ran L; Xie L; Wang Y; Gao L; Tian Q; Zhou X; Sun B; Xu L; Tang Z; Ye L
    Cell; 2022 Oct; 185(22):4049-4066.e25. PubMed ID: 36208623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive profile of TCF1
    Wang D; Fang J; Wen S; Li Q; Wang J; Yang L; Dai W; Lu H; Guo J; Shan Z; Xie W; Liu X; Wen L; Shen J; Wang A; Chen Q; Wang Z
    Int J Oral Sci; 2022 Feb; 14(1):8. PubMed ID: 35153298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity.
    Kim MY; Jayasinghe R; Devenport JM; Ritchey JK; Rettig MP; O'Neal J; Staser KW; Kennerly KM; Carter AJ; Gao F; Lee BH; Cooper ML; DiPersio JF
    Nat Commun; 2022 Jun; 13(1):3296. PubMed ID: 35697686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
    Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
    J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA.
    Kim A; Oh MS; Lee GH; Song S; Byun MS; Choi D; Yu BY; Lee H
    Antib Ther; 2024 Apr; 7(2):105-113. PubMed ID: 38566969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.